University lecturer, Guillaume Bastiat coordinates a maturation program on intimal hyperplasia with the Satt Ouest Valuation. He discusses the first results and the future of this innovative project, which ends at the beginning of 2025.
From left to right: Joohee Park, maturation engineer at Satt, Abhinandan Nandrajog, first year doctoral student, and Guillaume Bastiat. Following vascular surgery (bypass, arteriotomy), the blood vessel can narrow and heal in an uncontrolled manner: this is called intimal hyperplasia. Blood flow decreases and causes new cardiovascular problems for the already fragile patient. No valid curative therapeutic solution is proposed to date to counter this phenomenon, just a limitation of its development with a new surgical intervention by the installation of an endoprosthesis or a stent.
It is on this “ complex phenomenon » that Guillaume Bastiat, from the Translational Micro and Nanomedicines laboratory (Mint), has been working on since 2023. “ We use a hydrogel type biomaterial, a technology initially used to fight brain tumors and which was the subject of a patentexplains the researcher. It is an innovative secondary prevention strategy since there are no therapeutic solutions yet.. »
Soon an ANR project?
The gel is composed of lipid nanoparticles loaded with antiproliferative agent. Once the gel is deposited with a syringe on the outside of the blood vessel, around the vascular suture, the nanoparticles infuse into the walls of the vessel and release the molecules of interest to prevent and limit the uncontrolled proliferation of smooth muscle cells, without impact the initial post-operative healing process.
« We collaborated with the CarME team from the Mitovasc laboratory and the team of Jean Picquet, PU-PH and head of the vascular and thoracic surgery department at Angers University Hospital). The first results demonstrate that it is possible to release our molecules of interest into the arteries and partially limit intimal hyperplasia. It remains to find the optimal dosage and the best release profiles of the molecules of interest. The next stage of the project will be to approach companies with the Satt Ouest Valuation. »
At the same time, Guillaume Bastiat will submit a project to the National Research Agency (ANR) to target new biomarkers of intimal hyperplasia in order to prevent this phenomenon through new strategies, always in partnership with the CarME team and the Angers University Hospital, as well as with two laboratories from the Universities of Le Mans and Toulouse. “ We will see in 2025 if the file is accepted », he concludes.
Health
